In Loving Memory of Robert Ringdahl
In the words of his loving wife, Rose Wang

Alas, drug resistance kicked in two months later. At this point, we sought a second opinion and decided to give dual agent immunotherapy a try. The window was narrow but we had to try because we were running out of options. The side effects came on very strongly shortly after the first treatment and they set off one ER visit after another. After the second treatment, Robert got so weak from chronic GI bleeding (because Melanoma tumors are very vascular), he was hospitalized on September 20th. We almost lost him at the end of September due to complications. At that point, the oncologist declared the dual-agent immunotherapy did not work and switched back to the Targeted Therapy drugs in hopes that they would work a while after a drug holiday. Indeed, he woke up from a deep delirium miraculously.
Ultimately, we got a month of life extension from this last treatment and what a precious gift that was. Even during his last week on earth, I was searching frantically for another treatment. I attended the 2019 NFCR Scientific Symposium where I met a scientist from Harvard who is collaborating with a clinician at Dana Faber on a vaccine to treat advance cancer patents like Robert. It gave both of us hope, however momentarily that was. We quickly learned from the doctors that he did not qualify for the trial due to the fact that his liver was failing already. After spending a weekend with his kids and grandkids, and our wedding anniversary, he passed away peacefully on November 4, 2019.
We will miss Robert dearly, and are even more determined to continue his vision and dedication to those affected by cancer. Donations in his memory toward further research into cancer research can be made here.
[vc_template name=”A world without”]









